Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:04 AM
Ignite Modification Date:
2025-12-25 @ 4:04 AM
NCT ID:
NCT06361602
Eligibility Criteria:
Inclusion Criteria.
1. No restriction on nationality, age 18-55 years old (including borderline value), no restriction on gender;
2. Body weight: Male ≥50kg, female ≥45kg and 18.5kg/m2≤BMI≤30kg/m2 (BMI=Body Mass Index (BMI) = Weight (kg)÷Height (m)2);
3. Blood pressure:
12.0Kpa (90mmHg)≤systolic blood pressure≤18.7Kpa (140mmHg) 8.0Kpa (60mmHg) ≤ diastolic blood pressure ≤ 12.0Kpa (90mmHg);
4. Pulse: 60 beats/min ≤ pulse ≤ 100 beats/min, ≥ 50 beats/min for high endurance athletes, or rhythmic abnormalities without clinical significance;
5. Ear temperature: 35.7 ≤ body temperature ≤ 37.5 ℃;
6. Good general condition of the body: no damage to vital organs such as heart, lungs, liver, kidneys, etc., no serious or uncontrolled infections, no history of serious mental disorders;
7. Clinical examination should fulfill the following criteria:
7.1 Hemoglobin (Hb) measurement is normal or abnormal without clinical significance; 7.2 White blood cell (WBC) measurement: (3.5-10) × 109/L; 7.3 Platelet count (PLT) determination normal or abnormal without clinical significance; 7.4 Neutrophil count (NEU) determination normal or abnormal without clinical significance; 7.5 Normal or abnormal liver and kidney function test indexes without clinical significance; 7.6 Normal or abnormal coagulation function without clinical significance; 7.7 Hepatitis B virus surface antigen (HBsAg) negative; 7.8 Hepatitis C virus antibody (HCV antibody) negative; 7.9 human immunodeficiency virus antibody (HIV-1 and HIV-2 antibody) negative; 7.10 Syphilis negative;
Exclusion Criteria.
1. the following diseases considered clinically significant by the investigator: 1.1 Have respiratory, circulatory, gastrointestinal, urinary, hematologic, immunologic, endocrine system diseases or metabolic disorders; neurological disorders, psychiatric disorders, Creutzfeldt-Jakob disease, and those with a family history of the disease, or those who are receiving treatment with tissues or tissue derivatives that may have originated from infection with Creutzfeldt-Jakob pathogens; 1.2 Persons with chronic skin diseases, especially infectious, allergic or inflammatory systemic skin diseases; persons with allergic diseases or recurrent allergic attacks; 1.3 persons with malignant tumors or benign tumors affecting health;
2. those who have not completed 3 months of minor surgery, such as appendectomy, ophthalmic surgery after healing, etc.; those who have not completed 1 year of major surgery, such as: benign gynecological tumors, gastrointestinal malignant tumors after surgery, etc;
3. Women during pregnancy, less than 6 months after abortion, and less than 1 year after delivery and breastfeeding;
4. Less than 1 week after recovering from upper respiratory tract infection or less than 3 months after recovering from pneumonia;
5. less than 3 months after recovery from acute pyelonephritis, or during the period of urinary stone attack;
6. Injury caused by equipment contaminated by blood or tissue fluid or contaminated wounds, or less than 1 year after tattooing;
7. Those who have received whole blood and blood component transfusion within 1 year;
8. within 2 weeks after the last vaccination with live attenuated measles, mumps, or polio vaccine, or within 4 weeks after the last immunization with live rubella vaccine or live attenuated encephalitis B vaccine;
9. Within 1 year after the last immunization with rabies vaccine after being bitten by an animal;
10. within 4 weeks of the last immunization with antitoxin or immune serum injection or within 1 year of the last immunization with hepatitis B human immunoglobulin injection
11. those who have a documented clinical trial with leukocyte, plasma, platelet, or whole blood donation within 3 months
12. who, in the opinion of the investigator, are not suitable for participation in this study.
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
55 Years
Study:
NCT06361602
Study Brief:
Protocol Section:
NCT06361602